Itranix Gel contains Itraconazole 1% w/w, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the topical treatment of superficial fungal infections of the skin, including dermatophytosis, candidiasis, and pityriasis versicolor. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itranix Gel is formulated for cutaneous application, allowing targeted delivery of the active ingredient to the affected area with minimal systemic absorption. This topical formulation is suitable for patients with localized fungal infections, providing effective relief from symptoms such as itching, redness, and scaling. The gel base ensures good skin penetration and a non-greasy feel, enhancing patient compliance. It is recommended to apply a thin layer of Itranix Gel to the affected area once or twice daily, as directed by a healthcare professional, for a duration typically ranging from 2 to 4 weeks depending on the severity and type of infection. Patients should avoid contact with eyes and mucous membranes. Use during pregnancy and lactation should be under medical supervision. Adverse effects are generally mild and may include local irritation or burning sensation.